Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Therapeutics, Inc. received an amended Schedule 13G/A from RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. reporting that, as of June 30, 2026, they collectively beneficially owned 0 shares of the company’s common stock, representing 0.0% of the class. The filing shows no sole or shared voting or dispositive power over any shares and confirms that each Reporting Person now holds 5 percent or less of this class of securities.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Therapeutics, Inc. (par value $0.001 per share, CUSIP 359616109).
As of June 30, 2026, the reporting persons may be deemed beneficial owners of 5,475,040 shares, representing 8.22% of the outstanding common stock. These shares are held by funds and separately managed accounts under Nantahala’s control. Each reporting person has shared voting power and shared dispositive power over 5,475,040 shares and no sole voting or dispositive power. Harkey and Mack file as control persons with respect to shares beneficially owned by Nantahala, an investment adviser.
Fulcrum Therapeutics, Inc. common stock is reported as beneficially owned by Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen in an Amendment No. 2 to a Schedule 13G. Montanova Capital and Aaron Cowen each report 3,680,921 shares, representing 5.5% of the common stock, with shared voting and dispositive power over these shares. Averill Master Fund reports 2,553,201 shares, representing 3.8% of the class, also with shared voting and dispositive power. All securities are directly owned by advisory clients of Montanova Capital, and the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Fulcrum Therapeutics, Inc. received an updated Schedule 13G/A (Amendment No. 2) from TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu. The reporting parties now report 0 shares of Fulcrum common stock beneficially owned, corresponding to 0% of the outstanding class.
Each reporting person lists no sole or shared voting or dispositive power over Fulcrum shares and affirms ownership of 5 percent or less of the common stock. They also disclaim beneficial ownership of any securities except to the extent of their pecuniary interest through the referenced entities.
Fulcrum Therapeutics, Inc. reported an executive leadership change in its finance organization. Vice President, Finance and principal accounting officer Greg Tourangeau, whose planned departure had been previously disclosed, will end his tenure on August 7, 2026. Effective the same date, the Board appointed chief financial officer and principal financial officer Alan Musso to also serve as principal accounting officer.
Musso’s background is described in the company’s definitive proxy statement filed on April 30, 2026. He will not receive additional compensation for assuming the principal accounting officer role. The company states there is no arrangement or understanding with any person regarding his appointment, no family relationships with other directors or executive officers, and no related-party transactions involving Musso that require disclosure under Item 404(a) of Regulation S-K.
Bank of America Corporation, through certain wholly owned subsidiaries, reports beneficial ownership of common stock of Fulcrum Therapeutics, Inc..
The group holds 4,468,123 shares of Fulcrum Therapeutics common stock, representing 6.7% of the outstanding class, based on 66,633,321 shares outstanding as reported by Fulcrum Therapeutics in its Form 10-Q for share totals as of April 20, 2026. All reported shares are held with shared voting and shared dispositive power; Bank of America and its reporting subsidiaries have no sole voting or dispositive power over these shares. The filing is made jointly on behalf of Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
Fulcrum Therapeutics, a rare‑disease drug developer, reported continued losses while fundamentally reshaping the business. After end‑of‑phase FDA feedback raised concerns about pociredir’s benefit‑risk profile in sickle cell disease, the company discontinued the program, ceased all research and development activities, and cut its workforce by about 85% from 57 to nine employees. Management is now conducting a comprehensive review of strategic alternatives, including a merger, acquisition, asset sale or licensing transaction, with Leerink Partners advising.
For the six months ended June 30, 2026, Fulcrum recorded a net loss of $45.1 million, compared with $35.0 million a year earlier, including $5.1 million of long‑lived asset impairments and $4.3 million of restructuring charges. Cash used in operations was $34.8 million. The company ended June with $318.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $639.3 million, and believes this liquidity will fund operating and capital needs for at least 12 months while it pursues potential transactions.
BlackRock, Inc. filed Amendment No. 4 reporting its beneficial ownership of common stock of THERAPEUTICS INC (symbol FULC). BlackRock reports beneficial ownership of 4,802,880 shares of common stock, representing 7.2% of the class.
BlackRock has sole voting powersole dispositive power
Kevin Tang and affiliated Tang Capital entities, as 10% owners of Fulcrum Therapeutics, reported indirect open-market purchases totaling 167,616 shares of common stock on July 16–17, 2026. Reported weighted-average prices were $3.56 and $3.52 per share, with trade ranges from $3.46 to $3.60. These shares are held through Tang Capital funds, and the trades were not reported under a Rule 10b5-1 trading plan.
BlackRock Portfolio Management LLC reported a passive ownership stake in THERAPEUTICS INC common stock on a Schedule 13G. The firm disclosed beneficial ownership of 4,021,379 shares, representing 6.0% of the outstanding common stock as of June 30, 2026.
BlackRock Portfolio Management LLC has sole voting power over 3,604,410 shares and sole dispositive power over 4,021,379 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying persons who may receive dividends or sale proceeds; according to the disclosure, no single such person holds more than five percent of the issuer’s outstanding common shares.